Loading...
•
Sep 30, 2024
Zomedica Q3 2024 Earnings Report
Zomedica's revenue increased by 10% to $7 million, with a gross margin of 72%, and maintained $78 million in liquidity.
Key Takeaways
Zomedica reported a 10% increase in revenue to $7.0 million for Q3 2024, driven by strong growth in the Diagnostics segment. The company's gross margin was 72.3%, and it maintains a strong liquidity position of $78 million.
Revenue for the third quarter of 2024 grew slightly more than 10% to $7.0 million.
Diagnostics revenue grew by 38%, and Capital revenue grew by 21% over the prior year quarter.
Gross margin was 72.3% for the third quarter of 2024.
Zomedica had cash, cash equivalents, and available-for-sale securities of $77.8 million as of September 30, 2024.
Zomedica
Zomedica
Zomedica Revenue by Segment
Revenue by Segment
Diagnostics Revenue
CapyFin.com Forward Guidance
Zomedica anticipates a strong finish to 2024 and a position of strength moving into 2025, supported by its balance sheet.
Positive Outlook
- Positioned to finish 2024 strong.
- Move into 2025 from a position of strength.
- Aggressively execute on strategy.
- Drive accelerated adoption of innovative portfolio.
- Expand on a global scale.